Home > Letter from the Editor

Letter from the Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University, Germany
MS Virtual 2020
Dear Reader, Scientists, physicians, healthcare professionals were eagerly looking forward to the joint ACTRIMS/ECTRIMS meeting held every third year, scheduled to take place in Washington DC in September. The organisers met the challenges of putting together the first virtual ACTRIMS/ECTRIMS meeting with some 45,000 „digital attendants“. The extensive teaching and scientific program covered all aspects of MS research, treatment, and care. New insights into the pathobiology, particularly of progressive MS, epidemiological aspects and lifestyle risk factors, MR and PET imaging, newer outcome measures, digital monitoring devices, data mining of trial extension studies, large scale registries, and experimental therapeutics were presented. The comprehensive trials of various Bruton’s tyrosine kinase inhibitors modulating B cell and microglial functions were discussed. Noteworthy was the positive outcome of the study using the tyrosine kinase inhibitor masitinib. ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on